

*Interview Summary Okay  
Eui DeJong 9/17/2005*

## REMARKS

This paper is in response to the Office Communication dated May 20, 2005 in which the Examiner indicates that the response to the restriction requirement of January 26, 2005 is not fully responsive. Specifically, the Examiner has required Applicants to elect one of the differentially expressed proteins identified by the instantly claimed methods asserting that "this sequence election is part of the invention election and not a specie election requirement". In response to this Communication, Applicants, through their undersigned attorney, requested a telephonic interview with Examiner DeJong and his supervisor, Examiner Brusca to discuss this requirement. At the outset, Applicant's wish to thank Examiners DeJong and Brusca for taking the time to conduct an interview regarding this application.

As explained during the interview, the present invention provides a drug screening method to assess the efficacy of agents useful for modulating insulin sensitivity. The method is performed by first identifying those proteins which are differentially expressed in insulin resistant, insulin sensitive and normal subjects in response to treatments which are known to alter insulin sensitivity. An insulin responsive tissue or subcellular fraction thereof is then contacted with the test agent, and the ability of the agent to modulate differential protein expression in the tissue is assessed. These results are then compared to those obtained from the treated insulin resistant, insulin sensitive and normal subjects thereby identifying test agents which modulate protein expression levels towards a more insulin sensitive or insulin resistant state. Because the expression pattern obtained in response to the test agent is compared to that obtained in response to known treatments, the skilled person can more accurately identify those agents which should have efficacy for the treatment of disorders relating to insulin sensitivity. Claim 1 has been amended to clarify the method being claimed. Support for the amendments to claim 1 can be found in original claims 8-13 and at page 13, line 24, over to page 14, line 34. Support for the recitation of the sample in step b) comprising "cellular tissue or a subcellular fraction thereof susceptible to the action of insulin" can be found at page 27, lines 24-31. It is respectfully submitted that the subject matter of